Atossa Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 12
- Market Cap
- $169.7M
- Introduction
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Conditions
- Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05607004
- Locations
- 🇺🇸
California Research Institute, Los Angeles, California, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05068388
- Locations
- 🇸🇪
Karma Study Centre, Stockholm, Sweden
Topical Endoxifen in Women
- Conditions
- Mammographic Breast Density
- Interventions
- Drug: PlaceboDrug: Topical endoxifen
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04616430
- Locations
- 🇸🇪
Karolinska Institutet, Stockholm, Sodersjukhuset, Sweden
AT-301 Nasal Spray in Healthy Adults
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04519788
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
- Conditions
- Female Breast CarcinomaFemale Ductal Carcinoma In Situ
- Interventions
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02540330
- Locations
- 🇺🇸
The Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
- Prev
- 1
- 2
- Next
News
Atossa's (Z)-Endoxifen Shows 77.7% Tumor Reduction in Phase 2 Breast Cancer Trial
Atossa Therapeutics' low-dose (Z)-endoxifen demonstrated significant tumor shrinkage with a 77.7% reduction in functional tumor volume in women with ER+/HER2- breast cancer during the I-SPY 2 trial.
Atossa Therapeutics Shifts Focus to Metastatic Breast Cancer with (Z)-Endoxifen, Strengthens Patent Portfolio
Atossa Therapeutics has strategically repositioned (Z)-endoxifen to target metastatic breast cancer, addressing a significant unmet medical need where current treatments offer limited durability and substantial side effects.
Atossa Therapeutics Unveils SMART 2.0 Study to Reduce Interval Breast Cancer in High-Risk Women
Atossa Therapeutics has proposed a pioneering Phase 3 clinical study called SMART 2.0 to investigate if oral (Z)-endoxifen can reduce interval breast cancer in high-risk women identified through advanced mammographic screening.
Nona Biosciences Expands Reach with Strategic Partnerships in Animal Health and Breast Cancer Therapeutics
Nona Biosciences has entered a strategic collaboration with Invetx to develop next-generation animal health biotherapeutics using their proprietary HCAb Harbour Mice® platform, marking their first expansion into the animal health sector.
Atossa Therapeutics' (Z)-Endoxifen Shows Promise in Phase 2 Breast Cancer Trial
Atossa Therapeutics presented Phase 2 EVANGELINE trial data at SABCS 2024, evaluating (Z)-endoxifen for ER+/HER2-negative breast cancer in premenopausal women.
Atossa's Endoxifen Shows Promise in Reducing Mammographic Breast Density in Phase II Trial
Novel selective estrogen receptor modulator (Z)-endoxifen demonstrates significant reduction in mammographic breast density in premenopausal women during Phase II KARISMA trial.
(Z)-Endoxifen Demonstrates Significant Reduction in Mammographic Breast Density in Phase 2 Trial
Atossa Therapeutics' Phase 2 KARISMA-Endoxifen trial shows (Z)-endoxifen significantly reduces mammographic breast density (MBD) in premenopausal women.